I'm not sure we can equate the two situations. I'm not familiar with the first one that you mentioned. In Medicago I can assure you, Mr. Masse, we're in solution mode. My first priority and everyone's priority should be to keep the jobs. We have 400 people, extremely talented people, in Quebec City.
The second thing is the facility, because we have amazing facilities that have been newly built. We want to protect that.
The third one is the IP. The thing about Medicago, and I've heard a lot of things, is that I think it's the first vaccine that has been approved in the last 20 years in Canada. It's a made-in-Canada vaccine, I should say. For me, this is quite significant. It's the first plant-based vaccine in the world. People look at Medicago today, but people should remember that when we did that at the time, as you remember, we wanted to invest in all the platforms of vaccines because no one knew exactly, at the time, which would work. Now, what I can tell you is that we're in solution mode. I spoke to the CEO of Mitsubishi Chemicals in Japan. I made sure to protect all our rights, but the focus as we speak today, my focus with the Government of Quebec and the mayor, is to protect jobs. It's about people.
Then I'll make sure that we have all our rights preserved, and we will retain our rights with respect to all sorts of arrangements we have. I want to thank my deputy, Simon Kennedy, because to your point, I think that our contribution agreements today have far more specificity in terms of protecting Canadian taxpayers with all the commitments they have to follow. Otherwise, we have recourse.